
Research team
Dr. Mohammed Assiri
MSc, PhD · Associate Professor of Pharmacology and Toxicology
College of Pharmacy, King Saud University, Riyadh 11451
Office 1A-10 — Lab 1B-68, Building 23
moassiri@ksu.edu.sa · +966 11 469 8190
Google Scholar · ORCID
Background
Professional Summary
Dr. Mohammed Assiri is an Associate Professor of Pharmacology and Toxicology at the College of Pharmacy, King Saud University. His research focuses on applying advanced omics technologies, particularly metabolomics and proteomics, to unravel the molecular mechanisms underlying drug action, toxicity, and disease progression.
Through integrative approaches using LC-MS, NMR, and proteomic profiling, Dr. Assiri investigates pharmacological mechanisms and identifies early biomarkers of toxicity in both in vitro and in vivo models. His work spans multiple areas, including diabetes, diabetic nephropathy, and the molecular safety and toxicity of electronic cigarettes, traditional cigarettes, and dental products.
Dr. Assiri has trained and supervised several graduate students, and has initiated and led multiple research collaborations at national and international levels, contributing to multidisciplinary projects that bridge basic science with clinical and regulatory relevance.
Research Interests
- Metabolomics and proteomics in toxicology — applying omics-based approaches to identify molecular signatures and pathways involved in chemical and drug-induced toxicity
- Biomarker discovery — identifying early diagnostic and predictive biomarkers for toxicity and disease using advanced LC-MS and NMR-based metabolomics
- Diabetes and diabetic nephropathy — exploring metabolic and proteomic alterations associated with diabetes and its complications, particularly kidney damage
- Molecular toxicity of xenobiotics — comparing the biological impact of xenobiotics in in vitro and in vivo models to assess potential health risks
Research Goals
- To elucidate the molecular mechanisms of drug-induced toxicity using integrated metabolomics and proteomics, identifying early biomarkers and disrupted pathways that contribute to adverse drug reactions
- To investigate metabolic and proteomic alterations associated with diabetes and its complications, particularly diabetic nephropathy, supporting the development of targeted therapeutic interventions
- To assess the molecular toxicity of emerging consumer products, including electronic cigarettes and dental materials, evaluating the long-term safety of widely used but under-regulated products
- To foster translational research through national and international collaborations that bridge experimental findings with clinical applications
Active now
Current Projects
Metabolomics- and proteomics-based biomarker discovery in human plasma.
Metabolomic and proteomic profiling of hyperglycemia-induced changes in HK-2 cells.
Investigation of NAD+ supplementation in diabetic nephropathy and longevity murine models.
Comparative molecular toxicity of electronic versus traditional cigarettes.
Safety and cytotoxicity assessment of dental materials and products.
Training and supervision
Graduate and PharmD Students
Current
- Enas Alsawaq, MSc (PhD student)
- Nour Alenazi (MSc student)
- Majed Alrubaie (PharmD)
- Satam Binhomran (PharmD)
Graduated
- Sahar AlJumayi, MSc
- Mohammed AlHamdan, PharmD
- Abdullah Alsulays, PharmD
Selected Publications
For a complete list, see Google Scholar or ORCID.
- Almohammed OA, Alsanea S, Albishi N, AlMuhareb L, AlMotawa R, Alrasheed S, Alasmari F, Almutairi F, Assiri MA, Alghamdi A. Evaluating the use of paracetamol to prevent fasting headache during the first week of Ramadan: A randomized, open-label, clinical trial. Headache. 2024.
- Alshamrani AA, Bin Salman SB, Alsaleh NB, Assiri MA, Almutairi MM, Almudimeegh S, Alwhaibi AM, As Sobeai HM. miRNA-driven sensitization of breast cancer cells to Doxorubicin treatment following exposure to low dose of Zinc oxide nanoparticles. Saudi Pharm J. 2024;102169.
- Schwab SK, Harris PS, Michel C, McGinnis CD, Nahomi RB, Assiri MA, Reisdorph R, Henriksen K, Orlicky DJ, Levi M. Quantifying Protein Acetylation in Diabetic Nephropathy from Formalin-Fixed Paraffin-Embedded Tissue. Proteomics Clin Appl. 2024.
- Alsaleh NB, Aljarbou AM, Assal ME, Assiri MA, Almutairi MM, As Sobeai HM, Alshamrani AA, Almudimeegh S, Hatshan MR, Adil SF. Synthesis, Characterization, and Toxicity Assessment of Zinc Oxide-Doped Manganese Oxide Nanoparticles in a Macrophage Model. Pharmaceuticals. 2024;17(2):168.
- Assiri MA, Al Jumayi SR, Alsuhaymi S, Emwas AH, Jaremko M, Alsaleh NB, Almutairi MM, Alshamrani AA, As Sobeai HM, Alghibiwi H. Electronic cigarette vapor disrupts key metabolic pathways in human lung epithelial cells. Saudi Pharm J. 2024;32(1):101897.
- Assiri MA, Albekairi TH, Ansari MA, Nadeem A, Attia SM, Bakheet SA, Shahid M, Aldossari AA, Almutairi MM, Almanaa TN. The Exposure to Lead (Pb) Exacerbates Immunological Abnormalities in BTBR T+ Itpr3tf/J Mice through the Regulation of Signaling Pathways Relevant to T Cells. Int J Mol Sci. 2023;24(22):16218.
- Alsuhaymi S, Singh U, Al-Younis I, Kharbatia NM, Haneef A, Chandra K, Dhahri M, Assiri MA, Emwas AH, Jaremko M. Untargeted metabolomics analysis of four date palm (Phoenix dactylifera L.) cultivars using MS and NMR. Nat Prod Bioprospect. 2023;13(1):44.
- Alsaleh NB, Assiri MA, Aljarbou AM, Almutairi MM, As Sobeai HM, Alshamrani AA, Almudimeegh S. Adverse Responses following Exposure to Subtoxic Concentrations of Zinc Oxide and Nickle Oxide Nanoparticles in the Raw 264.7 Cells. Toxics. 2023;11(8):674.
- Alasmari F, Alasmari MS, Assiri MA, Alswayyed M, Rizwan Ahamad S, Alhumaydhi AI, Arif BI, Aljumayi SR, AlAsmari AF, Ali N. Liver metabolomics and inflammatory profiles in mouse model of fentanyl overdose treated with beta-lactams. Metabolites. 2023;13(8):965.
- Alotaibi AM, Alsaleh NB, Aljasham AT, Tawfik EA, Almutairi MM, Assiri MA, Alkholief M, Almutairi MM. Silver nanoparticle-based combinations with antimicrobial agents against antimicrobial-resistant clinical isolates. Antibiotics. 2022;11(9):1219.
- Alasmari F, Assiri MA, Ahamad SR, Aljumayi SR, Alotaibi WH, Alhamdan MM, Alhazzani K, Alharbi M, Alqahtani F, Alasmari AF. Serum metabolomic analysis of male patients with cannabis or amphetamine use disorder. Metabolites. 2022;12(2):179.
- Harris PS, Michel CR, Yun Y, McGinnis CD, Assiri MA, Ahmadi AR, Sun Z, Roede JR, Burchill MA, Orlicky DJ. Proteomic analysis of alcohol-associated hepatitis reveals glycoprotein NMB (GPNMB) as a novel hepatic and serum biomarker. Alcohol. 2022;99:35-48.
- Shearn CT, Fennimore B, Orlicky DJ, Gao YR, Saba LM, Battista KD, Aivazidis S, Assiri M, Harris PS, Michel C. Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response. Free Radic Biol Med. 2019;143:101-114.
- Ali HR, Assiri MA, Harris PS, Michel CR, Yun Y, Marentette JO, Huynh FK, Orlicky DJ, Shearn CT, Saba LM. Quantifying competition among mitochondrial protein acylation events induced by ethanol metabolism. J Proteome Res. 2019;18(4):1513-1531.
- Assiri MA, Ali HR, Marentette JO, Yun Y, Liu J, Hirschey MD, Saba LM, Harris PS, Fritz KS. Investigating RNA expression profiles altered by nicotinamide mononucleotide therapy in a chronic model of alcoholic liver disease. Hum Genomics. 2019;13:1-13.
- Ali H, Assiri MA, Shearn CT, Fritz KS. Lipid peroxidation derived reactive aldehydes in alcoholic liver disease. Curr Opin Toxicol. 2019;13:110-117.
- Assiri MA, Roy SR, Harris PS, Ali H, Liang Y, Shearn CT, Orlicky DJ, Roede JR, Hirschey MD, Backos DS. Chronic ethanol metabolism inhibits hepatic mitochondrial superoxide dismutase via lysine acetylation. Alcohol Clin Exp Res. 2017;41(10):1705-1714.
- Assiri M, Harris PS, Ali H, Liang Y, Shearn CT, Roede JR, Backos DS, Fritz KS. Chronic Ethanol Consumption Alters SOD2 Dynamics through Lysine Acetylation. Free Radic Biol Med. 2016;100:S98-S99.